AR004493A1 - Derivados de oxindol 3- sustituido util como moduladores de canales de potasio y composiciones farmaceuticas que lo contienen. - Google Patents

Derivados de oxindol 3- sustituido util como moduladores de canales de potasio y composiciones farmaceuticas que lo contienen.

Info

Publication number
AR004493A1
AR004493A1 ARP960102970A AR10297096A AR004493A1 AR 004493 A1 AR004493 A1 AR 004493A1 AR P960102970 A ARP960102970 A AR P960102970A AR 10297096 A AR10297096 A AR 10297096A AR 004493 A1 AR004493 A1 AR 004493A1
Authority
AR
Argentina
Prior art keywords
potassium channel
derivatives
channel modulators
oxindol
contain
Prior art date
Application number
ARP960102970A
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR004493A1 publication Critical patent/AR004493A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Derivados de oxindol 3-sustituido, útil como moduladores de canales de potasio, caracterizado por la fórmula (I), en donde: R es hidrógeno, hidroxi ofluoro, R1, R2, R3 y R4 son cada uno independientemente hidrógeno, alquilo de 1 a 4 átomos de carbono, halógeno, trifluormetilo, fenilo, p-metilfenilo ó p-trifluorometilfenilo, ó R1 y R2, R2 y R3, ó R3 y R4 están unidos uno con otro, para formar un anillo benzofusionado. R5 es hidrógeno o alquilo de 1 a 4 átomosde carbono y R6 es cloro o trifluorometilo, o una sal, solvato o hidrato de los mismos no tóxico, farmacéuticamente aceptable del mismo.
ARP960102970A 1995-06-07 1996-06-06 Derivados de oxindol 3- sustituido util como moduladores de canales de potasio y composiciones farmaceuticas que lo contienen. AR004493A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/477,047 US5565483A (en) 1995-06-07 1995-06-07 3-substituted oxindole derivatives as potassium channel modulators

Publications (1)

Publication Number Publication Date
AR004493A1 true AR004493A1 (es) 1998-12-16

Family

ID=23894292

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960102970A AR004493A1 (es) 1995-06-07 1996-06-06 Derivados de oxindol 3- sustituido util como moduladores de canales de potasio y composiciones farmaceuticas que lo contienen.

Country Status (26)

Country Link
US (2) US5565483A (es)
EP (1) EP0747354B1 (es)
JP (1) JP4011135B2 (es)
KR (1) KR100432157B1 (es)
CN (1) CN1076348C (es)
AR (1) AR004493A1 (es)
AT (1) ATE195515T1 (es)
AU (1) AU707760B2 (es)
BR (1) BR1100180A (es)
CA (1) CA2176183C (es)
CZ (1) CZ289248B6 (es)
DE (1) DE69609772T2 (es)
DK (1) DK0747354T3 (es)
ES (1) ES2148685T3 (es)
GR (1) GR3034523T3 (es)
HK (1) HK1003301A1 (es)
HU (1) HU222046B1 (es)
IL (1) IL118349A (es)
NO (1) NO304829B1 (es)
NZ (1) NZ286748A (es)
PL (1) PL184660B1 (es)
PT (1) PT747354E (es)
RU (1) RU2165925C2 (es)
SG (1) SG70572A1 (es)
TW (1) TW384284B (es)
ZA (1) ZA964327B (es)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW504504B (en) * 1996-11-26 2002-10-01 Bristol Myers Squibb Co 4-aryl-3-hydroxyquinolin-2-one derivatives as ion channel modulators
HUP0002449A3 (en) * 1997-05-30 2001-12-28 Bristol Myers Squibb Company W Process for producing 3-fluoro oxindole derivatives and intermediates of the preparation
US5893085A (en) * 1997-06-10 1999-04-06 Phillips; Ronald W. Dynamic fuzzy logic process for identifying objects in three-dimensional data
US5972894A (en) * 1997-08-07 1999-10-26 Cytran, Inc. Peptides having potassium channel opener activity
CA2301549A1 (en) * 1997-08-28 1999-03-04 Piyasena Hewawasam 4-aryl-3-aminoquinoline-2-one derivatives as potassium channel modulators
AU5487199A (en) * 1998-08-14 2000-03-06 Elan Pharmaceuticals, Inc. Novel esk potassium channel polypeptide and polynucleotide compositions
AU1648600A (en) * 1998-12-04 2000-06-26 Neurosearch A/S Use of isatin derivatives as ion channel activating agents
PT1133474E (pt) * 1998-12-04 2007-04-30 Bristol Myers Squibb Co Derivados da 4-arilquinolin-2-ona substituidos em 3 posições utilizados como moduladores do canal de potássio.
US6355648B1 (en) * 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6391907B1 (en) * 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
JP2003506355A (ja) * 1999-08-03 2003-02-18 アボット・ラボラトリーズ カリウムチャンネル開放剤
US6992081B2 (en) 2000-03-23 2006-01-31 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
JP2003528071A (ja) * 2000-03-23 2003-09-24 エラン ファーマスーティカルズ インコーポレイテッド アルツハイマー病治療用組成物および方法
AU7388701A (en) * 2000-06-29 2002-01-08 Neurosearch As Use of 3-substituted oxindole derivatives as kcnq potassium channel modulators
US20030096864A1 (en) * 2000-06-30 2003-05-22 Fang Lawrence Y. Compounds to treat alzheimer's disease
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
US6846813B2 (en) 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
CN1217920C (zh) 2000-06-30 2005-09-07 艾兰制药公司 治疗早老性痴呆的化合物
US20020045566A1 (en) * 2000-10-13 2002-04-18 Gribkoff Valentin K. Selective maxi-K potassium channel openers functional under conditions of high intracellular calcium concentration, methods and uses thereof
TWI287984B (en) * 2000-10-17 2007-10-11 Wyeth Corp Pharmaceutical composition for modulating bladder function
CA2438805A1 (en) * 2001-02-20 2002-08-29 Bristol-Myers Squibb Company Fluoro oxindole derivatives as modulators of kcnq potassium channels
US6855829B2 (en) 2001-02-20 2005-02-15 Bristol-Myers Squibb Company 3-fluoro-2-oxindole modulators of KCNQ potassium channels and use thereof in treating migraine and mechanistically related disease
US6469042B1 (en) * 2001-02-20 2002-10-22 Bristol-Myers Squibb Company Fluoro oxindole derivatives as modulators if KCNQ potassium channels
WO2002080898A2 (en) * 2001-04-04 2002-10-17 Wyeth Methods for treating hyperactive gastric motility
CA2452039A1 (en) * 2001-06-27 2003-01-09 Elan Pharmaceuticals, Inc. Beta-hydroxyamine derivatives useful in treatment of alzheimer's disease
RS81904A (en) * 2002-03-20 2007-02-05 Bristol-Myers Squibb Company, Phosphate prodrugs of fluorooxindoles
US7244756B2 (en) 2002-06-26 2007-07-17 Poseidon Pharmaceuticals A/S Benzimidazol-2-one derivatives and their use
TWI271402B (en) * 2002-10-15 2007-01-21 Tanabe Seiyaku Co Large conductance calcium-activated K channel opener
US7632866B2 (en) 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
EP1553932A2 (en) * 2002-10-21 2005-07-20 Ramot at Tel Aviv University Ltd. Derivatives of n-phenylanthranilic acid and 2-benzimidazolon as potassium channel and/or cortical neuron activity modulators
KR100456679B1 (ko) * 2002-11-14 2004-11-10 현대모비스 주식회사 차량의 조수석 에어백의 장착구조
US6916937B2 (en) * 2003-02-03 2005-07-12 Bristol-Myers Squibb Company Carbohydrate prodrugs of fluorooxindoles
TW200508197A (en) * 2003-03-31 2005-03-01 Ucb Sa Indolone-acetamide derivatives, processes for preparing them and their uses
US7524664B2 (en) 2003-06-17 2009-04-28 California Institute Of Technology Regio- and enantioselective alkane hydroxylation with modified cytochrome P450
CA2532248A1 (en) * 2003-07-15 2005-02-03 Smithkline Beecham Corporation Novel compounds
WO2005035498A1 (ja) * 2003-10-08 2005-04-21 Dainippon Sumitomo Pharma Co., Ltd. 含窒素二環性化合物の摂食調節剤としての用途
CA2547283C (en) * 2003-11-26 2010-11-09 Pfizer Products Inc. Aminopyrazole derivatives as gsk-3 inhibitors
US7169803B2 (en) * 2004-03-15 2007-01-30 Bristol-Myers Squibb Company N-substituted prodrugs of fluorooxindoles
GT200500317A (es) * 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
GT200500321A (es) 2004-11-09 2006-09-04 Compuestos y composiciones como inhibidores de proteina kinase.
HU0500126D0 (en) * 2005-01-26 2005-04-28 Sanofi Aventis New compounds and process for their preparation
HU0500157D0 (en) * 2005-02-01 2005-04-28 Sanofi Aventis New compounds
HUP0500167A2 (en) * 2005-02-02 2007-03-28 Sanofi Aventis Optically active 4-chloro-3-(5-chloro-3-alkyl-2-oxo-2,3-dihydro-1h-indol-3-yl)benzoic acid derivatives and process for producing them
CA2605554A1 (en) * 2005-04-22 2006-11-02 Wyeth Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists
TW200719886A (en) * 2005-04-22 2007-06-01 Wyeth Corp Dihydrobenzofuran derivatives and uses thereof
GT200600164A (es) * 2005-04-22 2007-03-14 Derivados de dihidrobenzofuranos y usos de los mismos
JP2008538784A (ja) * 2005-04-24 2008-11-06 ワイス 膀胱機能を調節するための方法
US7576082B2 (en) * 2005-06-24 2009-08-18 Hoffman-La Roche Inc. Oxindole derivatives
AR054849A1 (es) * 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
TW200734334A (en) * 2006-01-13 2007-09-16 Wyeth Corp Treatment of substance abuse
AU2007231011A1 (en) * 2006-03-24 2007-10-04 Wyeth New therapeutic combinations for the treatment of depression
CL2007000773A1 (es) * 2006-03-24 2008-01-25 Wyeth Corp Uso de compuestos derivados de diazepina condensada para el tratamiento de un desorden cognitivo como add o adhd;o su uso para tratar spm o pmdd.
AU2007230997A1 (en) * 2006-03-24 2007-10-04 Wyeth Treatment of pain
US8252559B2 (en) * 2006-08-04 2012-08-28 The California Institute Of Technology Methods and systems for selective fluorination of organic molecules
US8026085B2 (en) * 2006-08-04 2011-09-27 California Institute Of Technology Methods and systems for selective fluorination of organic molecules
US8802401B2 (en) * 2007-06-18 2014-08-12 The California Institute Of Technology Methods and compositions for preparation of selectively protected carbohydrates
WO2009037707A2 (en) 2007-09-20 2009-03-26 Ramot At Tel Aviv University Ltd. N-phenyl anthranilic acid derivatives and uses thereof
CL2008002777A1 (es) * 2007-09-21 2010-01-22 Wyeth Corp Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario.
US20100204247A1 (en) * 2007-10-04 2010-08-12 Duffy Joseph L N-substituted oxindoline derivatives as calcium channel blockers
KR100985286B1 (ko) * 2007-12-28 2010-10-04 주식회사 포스코 내지연파괴 특성이 우수한 고강도 고망간강 및 제조방법
EP2540295A1 (en) 2011-06-27 2013-01-02 Centre national de la recherche scientifique Compositions for the treatment of Fragile X syndrome
TWI706952B (zh) 2015-04-29 2020-10-11 比商健生藥品公司 氮雜苯并咪唑類及其作為ａｍｐａ受體調控劑之用途
BR112017023200A2 (pt) * 2015-04-29 2018-08-07 Janssen Pharmaceutica Nv compostos de indolona e seu uso como moduladores do receptor de ampa
CN110545809A (zh) 2017-02-24 2019-12-06 奥维德医疗公司 治疗发作性疾病的方法
KR102612324B1 (ko) * 2019-01-25 2023-12-12 제이에프이 스틸 가부시키가이샤 고망간 강 주편의 제조 방법 및 고망간 강 강편 또는 강판의 제조 방법
CN110240558B (zh) * 2019-07-10 2022-05-27 上海华理生物医药股份有限公司 一种Flindokalner消旋体的新合成方法
KR102209406B1 (ko) * 2019-11-21 2021-01-29 주식회사 포스코 미세한 주조조직을 갖는 고망간강 및 그 제조방법과 이를 이용한 고망간 강판
EP3912625A1 (en) 2020-05-20 2021-11-24 Kaerus Bioscience Limited Novel maxi-k potassium channel openers for the treatment of fragile x associated disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3114351A1 (de) * 1981-04-09 1982-11-04 Hoechst Ag, 6000 Frankfurt "oxindol-derivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel mit neuroanaboler wirkung"
DE3803775A1 (de) * 1988-02-09 1989-08-17 Boehringer Mannheim Gmbh Neue substituierte lactame, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten
NZ239540A (en) * 1990-09-24 1993-11-25 Neurosearch As 1-phenyl benzimidazole derivatives and medicaments
US5200422A (en) * 1990-09-24 1993-04-06 Neurosearch A/S Benzimidazole derivatives, their preparation and use
SK278514B6 (en) * 1990-09-25 1997-08-06 Andreas Kiener Rhodococcus erythropolis microorganism and a method for producing hydroxylated pyrazines and quinoxalines
US5234947A (en) * 1991-11-07 1993-08-10 New York University Potassium channel activating compounds and methods of use thereof
FR2714378B1 (fr) * 1993-12-24 1996-03-15 Sanofi Sa Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant.

Also Published As

Publication number Publication date
ZA964327B (en) 1997-11-28
HU222046B1 (hu) 2003-04-28
CA2176183A1 (en) 1996-12-08
DK0747354T3 (da) 2000-09-18
CA2176183C (en) 2010-03-30
JP4011135B2 (ja) 2007-11-21
ES2148685T3 (es) 2000-10-16
PL314672A1 (en) 1996-12-09
BR1100180A (pt) 2000-03-14
US5565483A (en) 1996-10-15
CZ289248B6 (cs) 2001-12-12
JPH08333336A (ja) 1996-12-17
IL118349A0 (en) 1996-09-12
CN1144800A (zh) 1997-03-12
IL118349A (en) 2000-07-26
RU2165925C2 (ru) 2001-04-27
SG70572A1 (en) 2000-02-22
EP0747354B1 (en) 2000-08-16
KR970001324A (ko) 1997-01-24
HUP9601547A1 (en) 1997-09-29
ATE195515T1 (de) 2000-09-15
EP0747354A1 (en) 1996-12-11
AU707760B2 (en) 1999-07-22
NZ286748A (en) 1998-08-26
HK1003301A1 (en) 1998-10-23
CN1076348C (zh) 2001-12-19
DE69609772D1 (de) 2000-09-21
US5602169A (en) 1997-02-11
HU9601547D0 (en) 1996-08-28
DE69609772T2 (de) 2001-04-12
TW384284B (en) 2000-03-11
PL184660B1 (pl) 2002-11-29
NO962232L (no) 1996-12-09
PT747354E (pt) 2000-11-30
NO962232D0 (no) 1996-05-31
CZ161896A3 (en) 1997-03-12
AU5475796A (en) 1996-12-19
GR3034523T3 (en) 2000-12-29
KR100432157B1 (ko) 2004-10-06
NO304829B1 (no) 1999-02-22

Similar Documents

Publication Publication Date Title
AR004493A1 (es) Derivados de oxindol 3- sustituido util como moduladores de canales de potasio y composiciones farmaceuticas que lo contienen.
HUP0000079A2 (hu) Indán- és dihidroindolszármazékok
AR055878A1 (es) Derivados de ciclopropanocarboxamida
RS39704A (sr) Novi 1,2,4-tiadiazolijum derivati kao modulatori melanokortinskog receptora
DK0641328T3 (da) Broforbundne, azabicykliske derivater som substans P-antagonister
MX9504349A (es) Derivados de aroilpiperidina.
CO5550421A2 (es) Derivados de indol utiles para el tratamiento de enfermeda- des
HUP0001285A2 (hu) Proteáz inhibitor hatású pirrolidinszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények
YU59602A (sh) Aril fuzionisana azapoliciklična jedinjenja
FI943247A (fi) Piperatsiinijohdannaisia 5-HT-reseptoriantagonisteina
ES8106721A1 (es) Un metodo para la preparacion de derivados de ftalimidina
TR200100698T2 (tr) 5-HT4 alıcı-Antagonistleri olarak Dihidrobenzodioksin Karboksamit ve Keton türevleri
PT674621E (pt) Enantiomeros de derivados de carbazolo como agonistas do tipo 5-ht
AR007108A1 (es) Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes.
AR017221A1 (es) Compuestos abridores de los canales de potasio, y el uso de los mismos para la manufactura de un medicamento
NO995935D0 (no) 17<beta>-allyloksy(tio)alkyl-androstan-derivater for modulering av meiose
ES2132245T3 (es) Derivados de 1-azaadamantano como agonistas o antagonistas de 5-ht.
ES2128572T3 (es) Utilizacion de los derivados de cefem como agentes antimetastaticos.
NO923153L (no) Indol-derivater, deres fremstilling og bruk
PL312229A1 (en) Derivatives of abeo-ergoline as 5ht1a ligands
BG106079A (en) Cyclocarbamate derivatives as progesterone receptor modulators
HUT76276A (en) 3-substituted 1-arylindole compounds, pharmaceutical compositions containing them and their use
HUP9904402A2 (hu) Polihidroxi-fenol-származékok, alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények
GB2133012B (en) Quinazolines process for their preparation and pharmaceutical compositions containing them
SE8701524L (sv) Nya sulfonamider och deras framstaellningsfoerfarande